Author:
Lizandra Cortés P.,Poveda Verdú D.,Albert Férriz A.,Ñungo-Garzón N.C.,Domine M.C.,Sevilla-Mantecón T.,Pitarch-Castellano I.,Vázquez-Costa J.F.
Funder
Instituto de Salud Carlos III
Agència Valenciana de la Innovació
Reference17 articles.
1. Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus);Pitarch Castellano;Neurologia.,2022
2. Vazquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, et al. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts’ study. Eur J Neurol. 2022; Jul, doi: 10.1111/ene.15501.
3. New and developing therapies in spinal muscular atrophy: From genotype to phenotype to treatment and where do we stand?;Chen;Int J Mol Sci.,2020
4. 209th ENMC International Workshop: Outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 November 2014, Heemskerk, The Netherlands;Finkel;Neuromuscul Disord.,2015
5. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy;Vázquez-Costa;Eur J Neurol.,2022